Breast cancer is one of the most common malignancies in women. ERα, PR, and HER2 triple negative breast cancer (TNBC) is the current research focus because of the lack of effective targeted therapies. In our study, lentivirus systems were used to overexpress EZH2 and miR-1301 in TNBC cell lines. Western blot analysis and RT-qPCR were used to detect the protein and microRNA levels. The TCGA and Kaplan Meier plotter databases were used to analyze the EZH2 and miR-1301 expression levels in breast cancer. The effect of miR-1301 overexpression on cell proliferation, migration and colony formation were determined by using the sulforhodamine B (SRB) assay, wound healing assay and colony formation assay, respectively. Furthermore, an xenograft mouse model was used to investigate the function of miR-1301 overexpression in vivo. Finally, dual luciferase reporter assay was used to verify the binding site of EZH2 and miR-1301. We found that EZH2 induced the expression of miR-1301 in two TNBC cell lines, HCC1937 and HCC1806. Overexpression of miR-1301 suppressed TNBC cell proliferation, migration and colony formation, as well as the xenograft tumor growth in immunodeficient mice. Interestingly, miR-1301 inhibited the expression of EZH2 by binding to the 3′-UTR of EZH2 gene. These data suggest that EZH2 induces the expression of miR-1301 as a negative feedback control mechanism in TNBC.
Introduction
Breast cancer is a heterogeneous disease, encompassing a large number of entities with different morphological features and clinical behaviors [1] . The triple negative breast cancer (TNBC) is defined by the lack of estrogen-receptor alpha (ERα), progesterone receptor (PR) and human epidermal growth factor receptor 2 alpha (HER2) expression [2] . TNBC has a more aggressive clinical outcome than other subtypes of breast cancer and there are no effective targeted therapies for TNBC [3] . Therefore, it is important to identify biomarkers and therapeutic targets for TNBC.
Polycomb protein histone methyltransferase enhancer of Zeste homolog 2 (EZH2) is a core catalytic subunit of the polycomb repressive complex 2 (PRC2), which epigenetically mediates transcriptional gene silencing and chromatin remodeling by specifically catalyzing the trimethylation of histone H3 at lysine 27 (H3K27me3) [4, 5] . EZH2 is frequently overexpressed in a wide variety of human malignancies including breast, prostate, bladder, colon, lung, pancreatic cancer, sarcoma and lymphoma, and overexpression of EZH2 is often correlated with advanced stages of human cancers and poor prognosis [6, 7] . Accumulating evidence demonstrates that EZH2 is essential for cancer initiation, development, progression, metastasis, and drug resistance [8] . In breast cancer, a higher EZH2 expression level is associated with aggressive basal-like subtype and poor metastasis-free survival [9, 10] . Down-regulation of EZH2 inhibits cell proliferation, induces cell cycle arrest, suppresses tumorigenicity, and improves survival of mice with ERα-negative invasive breast carcinoma [11] . Consistently, EZH2 may serve as a prognostic biomarker and target in TNBC.
MicroRNAs (miRNAs) are a set of endogenous small noncoding RNAs about 20-25 nucleotide (nt), which serve as posttranscriptional regulators by binding to the 3′-UTR of mRNA [12] . It has been reported that miRNAs play important roles in many aspects of cellular processes, including proliferation, migration/invasion, differentiation, cell cycle progression, and apoptosis [13] [14] [15] [16] . Several miRNAs, including miR-25, miR-26a, miR-30d, miR-98, miR-101, miR-124, miR-137, miR-138, miR-144, miR-214, miR-340, miR-let-7, and miR-let-7a have been shown to directly target EZH2 in cancer cells [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . Down-regulation of these miRNAs and the resulting up-regulation of EZH2 seem to be critical for the aggressive behaviors of various cancers [8] .
miR-1301 has been shown to be down-regulated in breast cancer, prostate cancer, liver cancer, lung cancer, and glioma [29] [30] [31] [32] . miR-1301 inhibits cell proliferation, survival, migration, invasion, epithelial-mesenchymal transition, angiogenesis, and metastasis [29] [30] [31] [32] . However, it has also been reported that miR-1301 is upregulated in prostate cancer and liver cancer cell lines and miR-1301 promotes anchorage-dependent and independent growth, colony formation, cell migration, and angiogenesis [33, 34] . Thus, the regulatory mechanism of miR-1301 and its functions are unclear.
In this study, we found that EZH2 positively regulates the expression of miR-1301 and miR-1301 negatively regulates the expression of EZH2 in TNBC cell lines. Functionally, miR-1301 inhibits not only TNBC cell proliferation, migration and colony formation in vitro, but also xenograft tumor growth in immunodeficient mice. Therefore, miR-1301 is a tumor suppressor in TNBC and serves as a negative feedback regulator for EZH2.
Materials and Methods

Cell culture
All cell lines used in this study were purchased from the American Type Culture Collection (ATCC, Manassas, USA) and validated by short tandem repeat (STR) analysis. MDA-MB-231 cells were cultured in DMEM/F12 medium (Thermo Fisher, Waltham, USA) supplemented with 10% fetal bovine serum (FBS; Thermo Fisher). SUM149PT cells were cultured in Ham's F12 medium (Hyclone, Logan, USA) with 10% FBS, 5 μg/ml insulin and 1 μg/ml hydrocortisone. HCC1937 and HCC1806 cells were cultured in RPMI 1640 medium (Thermo Fisher) supplemented with 10% FBS. HEK293T cells were maintained in DMEM medium (Thermo Fisher) with 5% FBS. All cell lines were cultured in a humidified atmosphere containing 5% CO 2 at 37°C.
Cell infection and transfection
MDA-MB-231 and HCC1806 cells were seeded in a 6-cm cell culture dishes with a density of 3. 
Dual luciferase reporter assay
The wild-type EZH2 3′-UTR or miR-1301 binding site mutated counterpart was cloned into the psiCHECK 
Western blot analysis
Western blot analysis was performed as described in our previous study [35] . In brief, the cells were treated for indicated time and then collected in lysis buffer containing protease inhibitors (P8340; Sigma). The cell lysates were centrifuged and the supernatants were collected, mixed with sample loading buffer and boiled for 10 min. The samples were then subject to 10% SDS-PAGE and transferred onto polyvinylidene fluoride (PVDF) membranes (0.45 μm; Merk Millipore, Darmstadt, Germany). The primary antibodies used in this study were rabbit anti-EZH2 antibody (1:1000; Cell Signaling, Danvers, USA), anti-p21 antibody (1:1000; Cell Signaling), anti-Bcl-xl antibody (1:1000; Cell Signaling), anti-AKT antibody (1:1000; Cell Signaling), anti-p-AKT(Ser473) antibody (1:1000; Cell Signaling), mouse antip27 antibody (1:1000; BD Biosciences, San Jose, USA), rabbit anti-GAPDH antibody (1:5000; Santa Cruz Biotech, Santa Cruz, USA), and mouse anti-β-actin antibody (1:5000; Sigma, St Louis, USA). The goat anti-rabbit and goat anti-mouse HRP conjugated-secondary antibodies (1:5000) were from Thermo Scientific.
RNA extraction and quantitative real-time PCR
Total RNA was extracted from cells using Trizol reagent (Invitrogen, Carlsbad, USA). Reverse transcription was performed using the TaqMan PCR MicroRNA Reverse Transcription Kit (Applied Biosystems, Austin, USA). For quantitative real-time PCR, SYBR PCR Master Mix (Applied Biosystems) was used to quantify the expression level of RNA on a 7900HT Fast Real-Time PCR System (Applied Biosystems). U6 was used as an internal control. Equal amounts of total RNA (1 μg) for each sample were converted into cDNA by reverse transcription reaction. A 20 μl reaction mixture containing 1 μl cDNA template were used in RT-qPCR. The PCR conditions were 50°C for 2 min, 95°C for 2 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The fold change of RNA expression was calculated based on the threshold cycle (Ct) using the 2 −ΔΔCt method. All primers used in this study were listed in Table 1 .
Cell viability analysis
The cell viability was measured by the sulforhodamine B (SRB) assay [36] . MDA-MB-231 and HCC1806 cells with stable overexpression of miR-1301 or control LV3-NC were seeded in 48-well plates at 8 × 10 3 cells/well. After incubation at 37°C for indicated time, we removed the medium and fixed the cells with 10% trichloroacetic acid (TCA; Fengchuan, Tianjin, China) at room temperature for 60 min, followed by incubating with 0.4% SRB (Sigma, Shanghai, China) solution in 1% acetic acid for 5 min at room temperature. Finally, SRB was dissolved with 10 mM unbuffered Tris base, and the absorbance was measured at a single wavelength of 530 nm on a plate reader (BioTek, Shoreline, USA). All experiments were performed in triplicates at least three times independently.
Wound healing and colony formation assays
The wound healing assay was performed in 12-well plates with 6 × 10 5 cells/well. Twenty-four hours after cell plating, wounds were generated using a pipette tip, and the wounds were recorded under a light microscope (OPTIKA SRL, Ponteranica, Italy) at different time points. Image analysis was conducted using Image-Pro Plus 6.0 software, the percentage of wound closure was calculated using the formula: (Width 0 h -Width 24 h )/Width 0 h × 100%. For the colony formation analysis, cells were seeded in 6-well plates with 500 cells per well and cultured for about 14 days. Then colonies were fixed with 0.4% formaldehyde for 30 min, and stained with 1% crystal violet for 30 min. Finally, colonies that contained more than 50 cells were counted under the light microscope. Image analysis was conducted using Image-Pro Plus 6.0 software. All experiments were performed at least three times.
Migration and invasion assays
The effect of miR-1301 on migratory and invasive capability was measured by Transwell assay. For the experiment, 7 × 10 4 cells/well were seeded into the cell culture inserts or precoated Matrigel matrix inserts (8-μm) using BD BioCoat™ BD Matrigel™ Invasion Chambers (BD, Franklin Lakes, USA), respectively. After incubation at 37°C for indicated time, and the inserts were collected and the migrated or invaded cells were fixed with 4% paraformaldehyde, stained with 0.1% crystal violet and photographed using the light microscope. Finally, the crystal violet was dissolved with 33% acetic acid, and the absorbance was measured at a single wavelength of 570 nm with the plate reader.
Tumorigenesis assay
Animal studies were approved by the institutional ethics committee of Kunming Institute of Zoology, Chinese Academy of Sciences. Twelve female nude mice were purchased from SJA Lab Animal (Changsha, China), and were housed in an SPF animal facility. The nude mice were divided into two groups randomly. MDA-MB-231 cells with stable overexpression of miR-1301 or LV3-NC were injected subcutaneously into the left and right flanks (6 × 10 5 cells/ spot) of 6-week-old nude mice. Tumor growth was monitored by measuring the tumor volume every 3 days with calipers and calculated using established methods [37] . All of the mice were sacrificed at the end of 50 days, and tumors were harvested and weighed.
Statistical analysis
All experiments were repeated at least three times, and the data were presented as the mean ± SD. Differences among groups were identified using Student's t-test. P < 0.05 was considered statistically significant.
Results
EZH2 positively regulates the miR-1301 expression in TNBC cell lines
It has been reported that the promoter hypermethylation is associated with the low expression levels of miR-1301 in prostate cancer [30] . EZH2, a histone methyltransferase, also regulates gene transcription through the epigenetic mechanism in TNBC. Therefore, we wondered whether EZH2 regulates the expression of miR-1301 in TNBC. First, an EZH2 small interference RNA was used to knockdown EZH2 in two TNBC cell lines, MDA-MB-231 and HCC1806 and found that the miR-1301 levels were significantly decreased (Fig. 1A) . Following that, we overexpressed EZH2 using a lentivirus system and found that EZH2 induced the expression levels of miR-1301 in two TNBC cell lines HCC1806 and HCC1937 (Fig. 1B) .
We analyzed the expressions of miR-1301 and EZH2 in TCGA database and found that both EZH2 and miR-1301 are highly expressed in breast cancer (Fig. 1C) . Furthermore, the expression levels of EZH2 and miR-1301 are positively correlated (Fig. 1D) . High expression levels of EZH2 and miR-1301 are associated with a shorter patient survival (Fig. 1E) . Thus, we concluded that EZH2 positively regulates the miR-1301 expression in TNBC.
MiR-1301 inhibits TNBC cell proliferation, migration and colony formation
To test whether miR-1301 regulates TNBC malignance, a lentivirus system was used to overexpress miR-1301 in MDA-MB-231 and HCC1806 cell lines (Fig. 2A) . Overexpression of miR-1301 dramatically inhibited cell proliferation in both cell lines (Fig. 2B) . Then, we measured cell migration and invasion by wound healing assay (Fig. 2C,D) and Transwell assay ( Fig. 2E-H) . Consistently, miR-1301 significantly inhibited cell migration and invasion. In addition, we performed colony formation assay and found that miR-1301 significantly reduced the number of colonies compared with the LV3-NC control (Fig. 2I,J) . These results indicated that miR-1301 functions as a tumor suppressor in TNBC cells in vitro.
MiR-1301 inhibits TNBC xenograft tumor growth in immunodeficient mice
To validate whether miR-1301 suppresses TNBC in vivo, MDA-MB-231 cells with stable overexpression of miR-1301 or control were injected subcutaneously into the 6-week-old female nude mice. The miR-1301 stable overexpression cell line was confirmed by quantitative real-time PCR, and the effect of miR-1301 on EZH2 protein level was confirmed by western blot analysis (Fig. 3A) . As expected, miR-1301 significantly suppressed tumor growth (Fig. 3B) . We harvested the tumors and compared their weights. Tumors from the miR-1301 overexpression group were significantly smaller than those from the control group (Fig. 3C,D) . Mouse body weights from two groups are similar (Fig. 3E) . These data indicated that miR-1301 inhibited TNBC growth in vivo.
MiR-1301 directly targets EZH2 in TNBC cell lines
Using the online miRNA target prediction software miRwalk, we found that miR-1301 may bind to the 3′-UTR of EZH2 mRNA. In previous studies, miR-26a and miR-101 were shown to directly target EZH2 in breast cancer [19, 38, 39] . To test whether miR-1301 indeed inhibits EZH2 like miR-26a and miR-101, we transiently transfected HCC1806 cells with miR-1301, miR-26a and miR-101 mimics and detect the EZH2 protein level by western blot analysis. As shown in Fig. 4A , miR-1301 indeed decreased the EZH2 protein level as miR-26a and miR-101 did. Furthermore, miR-1301 was more potent than miR-26a and miR-101. miR-1301 inhibited the EZH2 protein expression not only in HCC1806 cells but also in other TNBC cell lines, including MDA-MB-231, HCC1937, and SUM149PT (Fig. 4B) . A putative miR-1301 binding site at 3′-UTR of EZH2 was predicted by miRwalk (Fig. 4C) . To confirm whether miR-1301 targets EZH2 through this putative site, dual luciferase reporter assay was performed. Indeed, miR-1301 significantly suppressed the luciferase activity when the luciferase reporter gene was connected with wild-type EZH2 3′-UTR; when the binding site was mutated, miR-1301 could not decrease the luciferase activity (Fig. 4D) . And the increase of luciferase activity in mutant or vector group may probably be induced by miR-1301 or other reasons, which will be explored by further experiments. Taken together, these results suggested that miR-1301 directly targets EZH2 in TNBC cell lines.
MiR-1301 decreases p-AKT and Bcl-xl, but increases p27 and p21 protein levels in TNBC cell lines MiR-1301 has been reported to decrease the expression of Bcl-xl in HepG2 cells [29] . By western blot analysis, we confirmed that miR-1301 not only decreased the EZH2 protein levels but also decreased the anti-apoptosis protein Bcl-xl protein levels in two TNBC cell lines, MDA-MB-231 and HCC1806 (Fig. 4E) . Inhibition of EZH2 was shown to decrease the p-AKT level in human colon cancer stem cells [40] and increase the cell cycle dependent kinase inhibitor p21 and p27 levels in two lung cancer cell lines [41] . As expected, miR-1301 decreased the phosphorylated AKT protein levels and increased the p21 and p27 protein levels (Fig. 4E) . These results are in agreement with the growth inhibitory function of miR-1301 in TNBC cell lines.
Discussion
In this study, we found that miR-1301 is positively regulated by EZH2. MiR-1301 inhibits TNBC cell proliferation, migration, colony formation in vitro, and tumor growth in vivo. Furthermore, we demonstrated that miR-1301 directly targets EZH2 and regulates expression of several growth-and survival-related proteins. Our results suggest that miR-1301, as an EZH2 downstream gene, inhibits EZH2 by a feedback mechanism, and that miR-1301 functions as a tumor suppressor gene in TNBC.
The functions and action mechanism of miR-1301 in tumorigenesis are not completely clear. Several studies have suggested that miR-1301 is an oncogene. MiR-1301 was reported to be overexpressed in prostate cancer and promote prostate cancer cell proliferation through directly targeting PPP2R2C [33] . Similarly, miR-1301 was shown to be highly expressed in liver cancer and promote cell migration and angiogenesis by targeting the tumor suppressor KLF6-FL [34] . Furthermore, the miR-1301 level was upregulated in head and neck squamous cell carcinoma (HNSCC) [42] . In breast cancer, miR-1301 was shown to promote cell proliferation by directly targeting ICAT and activating Wnt/β-catenin signaling pathway [43] .
In sharp contrast, several studies have also suggested that miR-1301 is a tumor suppressor. It was reported that miR-1301 was down-regulated in hepatocellular carcinoma (HCC) and miR-1301 inhibited HCC cell migration, invasion, and angiogenesis through targeting BCL9 [31] . Consistently, Fang et al. [29] showed that miR-1301 inhibited HepG2 cell migration and invasion by upregulating p53 and downregulating Bcl-2 and Bcl-xl. Additionally, miR-1301 expression was found to be down-regulated in glioma and miR-1301 was found to inhibit human glioma cell proliferation by directly targeting N-Ras [32] . Thus, the role of miR-1301 may be context dependent.
Our results suggest that miR-1301 is a tumor suppressor in TNBC. This conclusion is inconsistent with a previous finding in breast cancer [43] . In that study, miR-1301 overexpression was found to promote MDA-MB-231 cell proliferation. This discrepancy could be caused by different overexpression systems. Nevertheless, we confirmed that miR-1301 overexpression inhibited MDA-MB-231 tumor growth in nude mice. Furthermore, we confirmed that miR-1301 decreased EZH2, p-AKT and Bcl-xl protein levels in both MDA-MB-231 and HCC1806. Besides these two targets, miR-1301 also increased the protein levels of p21 and p27.
MiR-1301 inhibits cell proliferation and migration in vitro and tumorigenesis in vivo. However, miR-1301 is associated with poor clinical outcomes based on Kaplan Meier plotter analysis results. This may be explained by the fact that miR-1301 is induced by EZH2, a well established oncogene whose expression is associated with poor clinical outcomes in breast cancer [44] .
How miR-1301 is regulated is an important scientific question. A previous study suggested that miR-1301 might be regulated by promoter methylation [30] . Here, we demonstrated that EZH2 positively regulates miR-1301 in TNBC cells. EZH2 may indirectly induce the expression of miR-1301. Although EZH2 represses gene transcription in general, it can also activate gene transcription. It has been reported that EZH2 collaborates with E2F1 to activate gene expression [45] . The exact mechanism by which EZH2 induces miR-1301 requires further investigation.
In conclusion, we demonstrated that miR-1301 is an EZH2 target gene and miR-1301 directly targets EZH2. MiR-1301 appears to be a tumor suppressor because it inhibits cell proliferation, migration, colony formation, and tumor growth. Thus, the EZH2 and miR-1301 may be used in triple negative breast cancer treatment. -2-EZH2-3′-UTR mutant) and miRNA mimics were transiently transfected into HEK293T cells for 48 h before the luciferase activity assay. NC is negative control miRNA. WT means wild-type EZH2-3′-UTR. Data were presented as the mean ± SD. **P < 0.01. (E) miR-1301 inhibited the EZH2, p-AKT, and Bcl-xl protein expression levels in MDA-MB-231 and HCC1806 cells. Meanwhile, miR-1301 increased the p21 and p27 protein levels. The protein expression levels were measured by western blot analysis. GAPDH was used as a loading control.
